SCHEMBL2910232

SCHEMBL2910232

COc1ccc(-c2cn(CCCNc3ccc([N+](=O)[O-])c(N)n3)cc2C(=O)N[C@@H](C)CO)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.34
POLB P06746 2/20 0.34
KDM4E B2RXH2 1/20 0.34
GSK3A P49840 2/20 0.33
GSK3B P49841 2/20 0.33
LMNA P02545 1/20 0.33
PTAFR P25105 1/20 0.33
ROCK1 Q13464 3/20 0.33
ROCK2 O75116 2/20 0.33
PRKCG P05129 1/20 0.33
PRKACA P17612 1/20 0.33
RPS6KB1 P23443 1/20 0.33
CDK2 P24941 1/20 0.33
MARK3 P27448 1/20 0.33
MAPK1 P28482 1/20 0.33
AKT1 P31749 1/20 0.33
AKT2 P31751 1/20 0.33
RPS6KA3 P51812 1/20 0.33
PRKX P51817 1/20 0.33
PRKCD Q05655 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2911586 1.00 MAPT (0.34) MAPTPOLBKDM4EGSK3AGSK3B
SCHEMBL2912533 0.92 GSK3B (0.34) MAPTPOLBGSK3AGSK3BLMNA
SCHEMBL2909788 0.92 GSK3B (0.34) MAPTPOLBGSK3AGSK3BLMNA
SCHEMBL2913577 0.91 AHR (0.37) GSK3AGSK3BALDH1A1SMN1; SMN2MEN1
SCHEMBL2911914 0.91 AHR (0.37) GSK3AGSK3BALDH1A1SMN1; SMN2MEN1
SCHEMBL2904127 0.91 MET (0.35) GSK3AGSK3BLMNAMAPK1ALDH1A1
SCHEMBL2911532 0.91 ALDH1A1 (0.41) MAPTPOLBGSK3AGSK3BLMNA
SCHEMBL2904664 0.91 CYP1A2 (0.34) MAPTPOLBGSK3AGSK3BLMNA
SCHEMBL2911193 0.91 MET (0.35) GSK3AGSK3BLMNAMAPK1ALDH1A1
SCHEMBL2911906 0.91 CYP1A2 (0.34) MAPTPOLBGSK3AGSK3BLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537099-B1 PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 NOVARTIS VACCINES & DIAGNOSTIC (US) 2010-08-11 EP disclosed